MetaCap

Neumora Therapeutics Inc. Company Profile

NASDAQ: NMRAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.3339-0.0131 (-3.78%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Neumora Therapeutics at a glance

Neumora Therapeutics Inc. (NASDAQ: NMRA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Watertown, MA. Neumora Therapeutics is led by Dr. Joshua Pinto Ph.D. and employs about 63 people. The company's shares have traded publicly since 2023.

At a market capitalization of $63.0 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001885522, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Neumora Therapeutics do?

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Neumora Therapeutics Inc.
Ticker
NASDAQ: NMRA
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Joshua Pinto Ph.D.
Employees
63
Headquarters
260 Arsenal Place, Watertown, MA, United States
Phone
857 760 0900
IPO year
2023
Market cap
$63.01M
SEC CIK
0001885522
Latest annual report
10-K · Mar 30, 2026

Companies similar to Neumora Therapeutics

NMRA peer companies
CompanyPrice% ChgMarket capCompare
ATRAAtara Biotherapeutics Inc.6.33-0.16%$64.49Mvs NMRA
TNYATenaya Therapeutics Inc.0.2866-3.99%$65.32Mvs NMRA
CSBRChampions Oncology Inc.4.34-1.36%$60.41Mvs NMRA
CRDFCardiff Oncology Inc.0.8528-4.46%$66.34Mvs NMRA
CHRSCoherus Oncology Inc.0.3698-4.47%$57.15Mvs NMRA
OKYOOKYO Pharma Limited1.07-7.76%$56.15Mvs NMRA
CGTXCognition Therapeutics Inc.0.5822-3.06%$55.37Mvs NMRA
AVXLAnavex Life Sciences Corp.0.5915-11.39%$54.83Mvs NMRA

Related